MRUS
Companies
NASDAQ
Merus N.V.
Health Care
$52.59
+$10.54 (+25.07%)
Price Chart
Overview
About MRUS
merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. our most advanced development programs use the biclonics® format. biclonics® are capable of simultaneously attacking tumors in multiple ways. for example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
Market Cap
$3.6B
Volume
49.7M
Avg. Volume
40.9M
P/E Ratio
-9.228206
Dividend Yield
0.00%
Employees
215.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.77
Moderate Correlation
Volatility
High (0.49)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, MRUS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$3.6B
Volume49.7M
P/E Ratio-9.23
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
February 28, 2025Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025